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1. Introduction 
In recent years, strategy in cancer therapy has been the use of high doses of toxic non-
specific agents and to investigate a range of new agents that specifically target tumour-
related molecules, in a variety of biological pathways. A basic knowledge of these pathways 
in the cancer cell is becoming fundamental for clinical practice since it can provide 
prognostic as well as predictive information for established therapies, and lead to the 
discovery of potential new targets. Two main therapeutic strategies may be followed to 
optimize cancer treatment: a better selection of patients who will benefit the most from a 
given hormonal o cytotoxic therapy, through the use of predictive markers determined by 
genomics and/or proteomics techniques and the development of new agents with 
innovative and tumour-specific mechanism of action. We have reviewed the consideration 
of Choline Kinase as a novel target for the development of new anticancer drugs (Campos et 
al., 2003). 
Breast cancer is a common and often fatal disease. Excluding cancers of the skin, that of the 
breast is the most common cancer among women, accounting for nearly one out of every 
three cancers diagnosed in American women. Each year over 186,000 new cases and 46,000 
deaths are reported in the United States alone (Harris et al., 1996). Five main molecular 
pathways are of particular interest in terms of new drug development in breast cancer: the 
estrogen receptor pathway, the tyrosine signal transduction pathway, the angiogenesis 
pathway, the cell cycle regulation pathway and the apoptosis (programmed cell death) 
pathway. We will focus in this review on new cytotoxic, apoptotic and cell-cycle-regulator 
agents, designed by our Group. 
As part of their action on neoplastic cells, many anticancer drugs activate apoptosis that 
may be a primary mechanism of antineoplastic agents (Hickman, 1992). Although breast 
cancer is most often treated with conventional cytotoxic agents it has proved difficult to 
induce apoptosis in breast cancer cells using these drugs (Rasbridge et al., 1994). Improved 
clinical response may be obtained by identifying therapies that are particularly effective in 
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activating apoptosis and determining how those therapies may be modified to effect 
maximum apoptosis induction. The cell cycle apparatus and apoptosis have recently 
attracted the attention of researchers intent on developing new types of anticancer therapy 
(Lundberg & Weinberg, 1999; Qin & Ng, 2002). On the other hand, the MCF-7 human breast 
cancer cell line has been used as an excellent experimental model to improve the efficacy of 
different therapies before its use in patients (Matsuo et al., 2000; Trouet et al., 2001). We will 
concentrate in this review on the evolution of the chemical structures and the biological 
properties whilst, in general, the chemical syntheses will be referred to through the 
corresponding original references.   
2. Benzo-fused seven-membered derivatives linked to pyrimidines 
Having previously reported the synthesis and anticancer activities of acyclic 5-fluorouracil 
(5-FU) O,N-acetalic compounds 1-2 (Campos et al., 1996), cyclic O,N-acetalic compounds 
was synthesized with the objective of increasing the lipophilicity of the target molecules. In 
this way we have reported the synthesis and anticancer activities of compounds 3 (Campos 
et al., 1997), 4-6 (Saniger et al., 2003a), 7 (Marchal et al., 2007), 8-9 (Saniger et al., 2003a) and 
trans-10 (Saniger et al., 2003b) (Figure 1). In all cases, the linkage between the 5-FU moiety 
and the seven-membered ring was carried out through its N-1 atom. 
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Fig. 1. Several 5-FU derivatives showing interesting antitumour activities.  
2.1 Antiproliferative activities of cyclic O,N-acetals 
The IC50 values of the 5-FU cyclic O,N-acetals are shown in Table 1 (entries 4-6, 8-10). 
The most active 5-FU-derived compounds are 4, 5 and 10 (entries 5, 6 and 11). Compound 3 
(entry 4) shows the least antiproliferative activity (IC50 = 23 ± 0.88 μM). The lipophilicity in 
this structure has been increased by means of a fused benzene ring, and an unsaturation has 
been introduced to give 8. An increase has been obtained in its antiproliferative activity (IC50 
= 14 ± 1.02 μM, entry 9). On comparing structures 8 and 4, it is worth emphasizing that the  
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Entry Compound clog Pa IC50 (μM)b Cell Cycle (48 h)
c Apoptosisd 
G0/G1 G2/M S 24 h 48 h 
1 Control   68.39 12.04 19.57 1.24 1.24 
2 5-FU -0.89e 2.75 58.07 2.10 39.38 56.75 52.81 
3 Ftorafur -0.18f 3  0.11 45.62 0.00 54.38 52.20 58.06 
4 3 0.86 23  0.88 50.99 18.51 30.49 46.63 53.92 
5 4 1.09 7  0.61 74.41 15.77 9.82 8.45 12.17 
6 5 1.16 4.5  0.33 73.41 13.15 13.44 1.50 3.50 
7 6 1.16 22  0.93 71.76 10.08 18.16 40.08 46.73 
8 7 0.87 5  0.25 69.01 11.38 19.61 5.30 5.22 
9 8 2.54 14  1.02 86.14 1.60 12.26 57.33 51.37 
10 9 0.70 69  2.31 68.61 9.60 21.79 54.33 35.49 
11 10 2.18 5.5  0.58 82.48 5.13 12.40 14.37 19.05 
a Calculated by a fragmental system based on Rekker’s method (Rekker & de Kort,1979), the CDR option 
of the PALLAS 2.0 programme (PALLAS FRAME MODULE, a prediction tool of physicochemical 
parameters, is supplied by CompuDrug Chemistry Ltd, PO Box 23196, Rochester, NY 14696, USA). bSee 
ref. (Campos et al., 2000). cDetermined by flow cytometry: see ref. (Saniger et al., 2003a). dApoptosis was 
determined using an annexin V-based assay (Chadderton et al., 2000). The data indicate the percentage 
of cells undergoing apoptosis in each sample. All experiments were conducted in duplicate and gave 
similar results. The data are means ± SEM of three independent determinations. eThe experimental log P 
value is –0.83 (Buur et al., 1985). fThe experimental log P value, measured by the octanol-buffer 
partitioning technique at pH 7.4 is –0.36  0.5 (Gulyaeva et al., 2003). 
Table 1. Antiproliferative activities, cell cycle dysregulation, and apoptosis induction in 
the MCF-7 human breast cancer cell line after treatment for 24 and 48 h for the 
compounds. 
bioisosteric change of carbon for oxygen and the saturation of the double bond in 
compound 4 increases the antiproliferative activity twice (IC50 = 7 ± 0.61 μM, entry 5). The 
introduction of a methoxy group into the benzene ring of 4 provokes different influences on 
the antiproliferative activities. Thus, the C-7 substitution produces an increase of the 
antiproliferative activity (5, IC50 = 4.5 ± 0.33 μM, entry 6), whilst if C-9 is the substituted 
position it gives rise to a decrease in the antiproliferative activity (6, IC50 = 22 ± 0.93 μM, 
entry 7). The structural nature of 9 (entry 10, Table 1) implies that this compound cannot be 
considered as a 5-FU prodrug and we suspected that the remaining compounds (entries 4-7, 
9-11, Table 1) would not be 5-FU prodrugs. To start with and to confirm it we decided to 
change the 5-FU moiety of 4 for the naturally occurring pyrimidine base uracil to produce 7, 
with the prospect of finding an antiproliferative agent endowed with a new mechanism of 
action (Marchal et al., 2007). 
2.2 Apoptosis induction of cyclic O,N-acetals 
Apoptosis has been studied in terms of cancer development and treatment with attempts 
made to identify its role in chemotherapeutic agent-induced cytotoxicity. Cytotoxic agents 
often induce only a fraction of the cells to become apoptotic. To fully exploit apoptosis as 
a mechanism of antineoplastic agent response, a larger proportion of cells need to be 
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recruited into apoptosis. Paclitaxel (Taxol®), cyclophosphamide and cytosine arabinoside 
are the only commonly used cytotoxic agents shown to elicit apoptosis in breast cancer 
cells (Meyn et al., 1995; Milas et al., 1995). Quantitation of apoptotic cells was done by 
monitoring the binding of fluorescein isothiocyanate (FITC)-labelled annexin V (a 
phosphatidylserine-binding protein) to cells in response to our title compounds as 
described (Chadderton et al., 2000). The apoptosis study shows that compounds 3, 6, 8 
and 9, at their IC50 concentrations, provoke early apoptosis in the cells treated for 24 and 
48 h. It is worth pointing out that compound 6 (entry 7) induces greater apoptosis at 48 h 
(46.73%) than at 24 h (40.08%) and so does compound 3 [48 h (53.92%) and 24 h (46.63%), 
entry 4]. The compounds that show the most important apoptotic indexes at 24 h are 8 
(57.33%, entry 9) and 9 (54.33%, entry 10), whereas at 48 h are 3 (53.92%, entry 4) and 8 
(51.37%, entry 9). These compounds are more potent as apoptosis inductors against the 
MCF-7 human breast cancer cells than paclitaxel (Taxol®), which induced programmed 
cell death of up to 43% of the cell population (Saunders et al., 1997). Accordingly, the 
early apoptotic inductions and the low IC50 values give rise to a significant antitumor 
activity. 
2.3 Cell cycle distribution of cyclic 5-FU O,N-acetals 
Cell cycle regulation has attracted a great deal of attention as a promising target for cancer 
research and treatment (Sampath & Plunkett, 2001; Gali-Muhtasib & Bakkar, 2002). The use 
of cell-cycle-specific treatments in cancer therapy has greatly benefited from the major 
advances that have been recently made in the identification of the molecular actors 
regulating the cell cycle and from the better understanding of the connections between cell 
cycle and apoptosis. As more and more “cell cycle drugs” are being discovered, their use as 
anticancer drugs is being extensively investigated (Gali-Muhtasib & Bakkar, 2002). To study 
the mechanisms of the antitumour and antiproliferative activities of the compounds, the 
effects on the cell cycle distribution were analyzed by flow cytometry. Control DMSO-
treated cell cultures contained 68.39% G0/G1-phase cells, 12.04% G2/M-phase cells and 
19.57% S-phase cells. Cyclic  O,N-acetals 4-10 (entries 5-11) provoke a G0/G1-phase cell cycle 
arrest whereas ftorafur [1-(2-tetrahydrofuranyl)-5-fluorouracil], a known prodrug of 5-FU, 
induces a S-phase cell cycle arrest. 
In fact, a correlation between treated cells with compounds 4-10 recruited in the G0/G1 
phase when treated at their IC50 concentrations, and their calculated lipophilicities by the 
CDR option of the PALLAS 2.0 programme: 
 log (% G0/G1) = 1.801 (±0.009) + 0.055 (±0.003) clog P (1) 
n = 7, r2 = 0.976, s = 0.006, F1,5 = 206.10, α < 0.001 
where n is the number of compounds, r2 is correlation coefficient, s is the standard 
deviation, F is the F ratio between the variances of observed and calculated activities, and 
data within parentheses are standard errors of estimate. This equation means that the more 
lipophilic the compound is the more cells are recruited in the G0/G1 phase. 
2.4 Modification of the molecular markers caused by the cyclic 5-FU O,N-acetals 
Due to the fact that the cyclic O,N-acetals accumulate the cells in the G1-phase the 
expression pattern of cyclin D1 was studied. This cyclin is one of the cyclin-dependent 
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kinase (CDK) activator subunits, specifically to CDK4, being responsible of the 
progression of the cell through the G1-phase. Compounds 4 and 10 gave rise to a 
spectacular inhibition of cyclin D1 up to its total disappearance. This fact did not take 
place with 5-FU because the cyclin D1 level increased in relation to those of the parental 
MCF-7 cells. On one hand, this would explain why these compounds accumulate the cells 
in the G1-phase (on inhibiting cyclin D1 the cell cannot progress to the S phase) and on the 
other, they show a different mechanism of action from the one shown by 5-FU: in short, 
they are not prodrugs. 5-FU Increases the cyclin D1 production so that cells pass in most 
cases toward the S phase where they are held back. It has been reported (Stacey, 2003) that 
cyclin D1 works as an active “switch” in the progression of the cellular cycle and that 
elevated levels of cyclin D1 promote the entry of the cell into the S phase. Moreover, 
compound 10 increases the expression of proteins p21 or p27 even up to double of the 
control. These proteins belong to the family INK2 of the CDK inhibiting proteins that 
work by hindering the association and activation of cyclins with their complexes (Sherr, 
2000) and hence they halt cells in the G1 and G2/M phases. Compounds also affect the 
cdc2 activity that, regulated by their corresponding cyclins A or B, is essential for the 
entrance into mitosis during the cellular cycle (Sherr, 1993). Compounds 4, 10 and 5, with 
the exception of 8 and 5-FU, significantly decrease the cdc2 activity. Cdc2 is needed 
during the cellular cycle in the final phase of G1, in the control point named “start” to be 
committed to the mitotic cycle. This is because at the end of G2 (at the beginning of the 
mitosis) (Lees & Harlow, 1993), the inhibition of cdc2 by the O,N-acetals implies the 
halting of the cycle in G1 and the non-entrance of the tumor cells in mitosis. The increase 
of the cdc2 expression caused by 5-FU is due to the fact that this higher activity is 
necessary for the cells to pass rapidly to the S phase, where cells are stopped by this 
fluoropyrimidine. Finally, compound 8 also significantly increases the cdc2 levels, which 
may be because its premature activation is one of the requirements for apoptosis (Shi et 
al., 1994); in fact this compound is the one that induces a higher proportion of 
programmed cellular death in the MCF-7 treated cells. 
2.5 Apoptosis markers 
Since the synthesized compounds induce very important apoptosis, we have carried out 
studies of the expression of some of the genes that intervene in this phenomenon, among 
which p53 and the family bcl-2 are outstanding. The tumour suppressor gene p53 
protects the integrity of the genome so that if the DNA of the cell is damaged by an 
agent, an overexpression of it is produced inducing the stopping in G1 for the repair of 
the damage, or if this is not possible, enter in apoptosis (Agarwal et al., 1995). On the 
other hand, the members of the family of proteins Bcl-2 work as regulators of apoptosis, 
Bcl-2 and Bcl-XL protecting against apoptosis. Bax, Bak and Bad induce such a 
phenomenon (Reed, 1997). 
The treatment of the MCF-7 cells (wild-type p53) with these compounds provoked in 
general an increase in the protein expression of p53, mainly for 5-FU and 8, and a marked 
decrease of the levels of bcl-2 for all of them. These data show that p53 activity is restored 
with the compounds, allowing the entrance of the tumour cells in apoptosis, which permits 
their elimination by this mechanism. In the same way bcl-2 inhibition facilitates the entrance 
of cells into the programmed cell death. 
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3. Benzo-fused seven-membered derivatives linked to purines 
Later on, we substituted the pyrimidine bases for the purine one (with several substituents 
at its position 6), with the objective of increasing both the lipophilicity and the structural 
diversity of the target molecules (Figure 2). Their syntheses (using conventional heating and 
microwave irradiation) and biological activities have been recently published (Conejo-
García et al., 2008). 
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Fig. 2. Reagents and conditions: Purine bases (12-18), TCS, HMDS, SnCl4, anhydrous MeCN. 
Method (a), (b) or (c): 45 ºC, 24-72 ºC; (b) microwave, 130 ºC, 5 min; (c) microwave, 100 ºC, 5 
min. 
3.1 Biological activities 
The antitumour potential of the target molecules is reported against the MCF-7 human 
breast cancer cell line including 5-FU as reference drug (Table 2) (Conejo-García et al., 2008). 
The purine O,N-acetals 19-32 are more active than their corresponding purine bases 12-18. 
The differences in the antiproliferative effect of the N-7’ and N-9’ regioisomers are not 
significant with the exception of the allyloxy derivatives 22 and 29. The biological effect is 
dependent on the substituent present on position 6 of the purine ring although a clear 
structure-activity relationship between the size of this moiety and the antiproliferative effect 
of the MCF-7 human breast cancer cell line is not observed. The most active compound (22), 
that presents an allyloxy group as substituent at position 6 of the purine ring, shows an IC50 
= 5.04 ± 1.68 μM nearly equipotent as 5-FU. The following two more active compounds, 23 
and 28, present bulky substituents as the phenylthio and 2,4-diclorophenylthio ones, 
respectively. 
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Compound IC50 (μM) Compound IC50 (μM) Compound IC50 (μM) 
5-FU 4.32 ± 0.02 19 11.6 ± 0.93 27 21.1 ± 2.93 
12 32.3 ± 1.42 20 24.7 ± 3.82 28 8.4 ± 0.91 
13 28.4 ± 0.45 21 12.0 ± 0.59 29 20.9 ± 1.24 
14 44.7 ± 0.74 22 5.04 ± 1.68 30 15.6 ± 3.74 
15 31.0 ± 0.16 23 7.12 ± 0.46 31 14.1 ± 0.67 
16 31.6 ± 0.54 24 11.2 ± 1.32 32 31.8 ± 5.46 
17 21.4 ± 0.42 25 24.0 ± 1.95   
18 23.6 ± 4.11 26 13.4 ± 1.94   
Table 2. Antiproliferative activities against the MCF-7 cell line for 5-FU (Núñez et al., 2007), 
for the purine bases (12-18), and for the seven-membered alkylated purine derivatives (N-9’ 
isomers: 19-25; N-7’ isomers: 26-32). 
To study the mechanisms of the antitumour and antiproliferative activities of the most 
active compounds (22, 23 and 28), the effects on the cell cycle distribution were analyzed by 
flow cytometry (Table 3). DMSO-treated cell cultures contained a 58.62 ± 0.74 of the G0/G1-
phase cells, a 33.82 ± 0.72 of the S-phase cells and a 7.55 ± 1.34 of the G2/M-phase cells. In 
contrast, MCF-7 cells treated during 48 h with the IC50 concentrations of 22, 23 and 28 
showed important differences in cell cycle progression compared with DMSO-treated 
control cells. The cell cycle regulatory activities can be divided into the following two 
groups: (a) the breast cancer cells showed an accumulation in the S-phase, up to 37.00 ± 2.00 
of the cells, mainly at the expense of the G0/G1-phase population that decreased to a 
percentage of 55.63 ± 1.57 of the cells; (b) compounds 23 and 28 accumulated the cancerous 
cells in the G2/M-phase (11.08 ± 1.01 and 19.16 ± 0.56, respectively) at the expense of the S-
phase cells (26.82 ± 1.26 and 22.73 ± 0.37, respectively). 
In response to 23 (and 28), the percentage of apoptotic cells increased, from 0.22 ± 0.31 in 
control cells to a maximum of 73.37 ± 0.12 (and 65.28 ± 1.92) apoptotic cells at a 
concentration equal to their IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult. 
 
Compound Cell cyclea Apoptosisb 
 G0/G1 S G2/M  
Control 58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
22 55.63 ± 1.57 37.00 ± 2.00 7.37 ± 0.43 44.47 ± 2.98 
23 59.10 ± 1.28 26.82 ± 1.26 11.08 ± 0.01 73.37 ± 0.12 
28 58.10 ± 0.19 22.73 ± 0.37 19.16 ± 0.56 65.28 ± 1.92 
a Determined by flow cytometry (Boulaiz et al., 2003). bApoptosis (48 h) was determined using an 
Annexin V-based assay (Boulaiz et al., 2003). The data indicate the percentage of cells undergoing 
apoptosis in each sample. All experiments were conducted in duplicate and gave similar results. The 
data are means ± SEM of three independent determinations. 
Table 3. Cell cycle distribution and apoptosis induction in the MCF-7 human breast cancer 
cell line after treatment for 48 h for the three most active compounds. 
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4. Anticancer and SAR studies on (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-
pyrimidine and -purine derivatives 
The synthesis and the mechanistic aspects of bioisosteres containing a 4,1-benzoxazepine N-
alkylated pyrimidine (33-45) or purine (46-58) (Figure 3) have been thoroughly discussed 
(Díaz-Gavilán et al., 2006; Díaz-Gavilán et al., 2007). 
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Fig. 3. New benzoxazepine O,N-acetals containing pyrimidine and purine rings. 
4.1 Antiproliferative activities 
Table 4 show the antiproliferative activity (IC50 values) on MCF-7 human breast cancer cells 
found for the pyrimidine and purine derivatives 33-58 (Díaz-Gavilán et al., 2008a). The most 
potent molecules were the purine derivatives. Compounds 48, 50, 52 and 57 presented IC50 
values below 1 µM. Between the pyrimidine derivatives 33-45, those containing 5-
fluorouracil (R2 = F) showed improved activities than those derived of uracil (R2 = H). 
Bonding of the pyrimidine ring through N-1” or N-3” affected the activity though only 
slightly, when R1 = H, 33 versus 40. The substitution on C-6” of the purine ring is essential 
for the activity1. Bulky, lipophilic groups afforded the best values of IC50 [R3 = Cl (46-52), -
SPh (57, 58)] while purinone compounds [R3 = OH (53-55)] were comparable to the 
pyrimidine analogues in terms of activity. Bonding of the purine ring through N-7” or N-9” 
                                                 
1 For the numbering of the compounds, the atoms of the benzoxazepine are tagged with numbers 
without primes, the atoms of the R1 group are numbered with primes (‘), while the pyrimidine and 
purine bases are numbered with double primes (“). 
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affected the activity to a lesser extent, and the positive or negative character of this effect 
depended on the nature of R1 (see 46/49 R1 = pNs, 47/50 R1 = oNs, 48/52 R1 = Fmoc). 
Both, pyrimidine and purine derivatives, were more potent when R1 is not hydrogen. The 
lipophilic character of R1 increased the activity and no limit of volume had been observed 
for the studied groups. The electron-withdrawing character of R1 could help to increase the 
activity (Díaz-Gavilán et al., 2004). Carbonyl derivatives were more potent than the sulfonyl 
ones. 
 
Compds IC50 (M) Compds IC50 (M) Compds IC50 (M) Compds IC50 (M) 
33 >100 40 72.40 ± 11.3 47 2.10 ± 0.69 54 19.66 ± 5.27 
34 19.33 ± 1.04 41 19.81 ± 0.08 48 0.67 ± 0.18 55 53.57 ± 13.1 
35 14.37 ± 0.69 42 22.63 ± 0.11 49 1.22 ± 0.12 56 48.92 ± 9.89 
36 19.70 ± 0.15 43 43.70 ± 0.09 50 0.92 ± 0.01 57 0.86 ± 0.12 
37 54.82 ± 1.04 44 44.28 ± 4.65 51 9.14 ± 1.24 58 2.59 ± 0.57 
38 39.78 ± 2.60 45 50.90 ± 3.87 52 0.84 ± 0.09   
39 45.17 ± 0.48 46 2.73 ± 0.17 53 >100   
Table 4. Antiproliferative activities against the MCF-7 cells for N-1”- (33-39) and N-3”- (40-
45) pyrimidines and for N-9”- (46-48) and N-7”-purines (49-58). 
When R1 = benzensulfonamido, it can be observed for pyrimidine and purine derivatives 
that the ortho-substitution on R1 is preferred to para, in terms of potency, and the nitro group 
renders better results than the amino one. As an exception, compound 57 (R1 = pNs, R3 = 
SPh), is more potent than 58 (R1 = oNs, R3 = SPh). The new related acyclic O,N-acetals 59-69 
(Figure 4) were obtained as minor products in the condensation reaction between the O,O-
acetals and pyrimidine (Díaz-Gavilán et al., 2006) or purine (Díaz-Gavilán et al., 2007) bases. 
Their antiproliferative activities have also been studied on MCF-7 human breast cancer cells 
and the IC50 values obtained are shown in Table 5. Acyclic purine O,N-acetals (67-69) show 
higher potency than the pyrimidine acyclic derivatives (59-66). The N-7”-alkylated purine 68 
presented an excellent value of IC50. In contrast to the cyclic analogues, the presence of an o-
NO2 or p-NO2 group does not modify the activity of the N-9”-isomers (67 and 69). 
 
N
N
OMe
OH
N
H
R1
O O
R2 N
N
OMe
OH
R1
N
N
N
R3
59 R1 = H, R2 = F
60 R1 = CO-C6H5, R2 = F
61 R1 = SO2-C6H4-pNO2, R2 = F
62 R1 = SO2-C6H4-oNO2, R2 = F
63 R1 = SO2-C6H4-oNH2, R2 = F
64 R1 = SO2-C6H4-pNO2, R2 = H
65 R1 = SO2-C6H4-pNO2, R2 = H (N-3")
66 R1 = SO2-C6H4-oNO2, R2 = H
  67 R1 = SO2-C6H4-pNO2, R3 = Cl
  68 R1 = SO2-C6H4-oNO2, R3 = Cl (N-7")
  69 R1 = SO2-C6H4-oNO2, R3 = Cl
 
Fig. 4. New acyclic O,N-acetals containing pyrimidine and purine moieties. 
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Compds IC50 (M) Compds IC50 (M) 
59 35.97 ± 0.40 65 55.22 ± 12.14 
60 16.14 ± 0.77 66 64.81 ± 0.05 
61 55.22 ± 12.14 67 18.70 ± 0.08 
62 90.99 ± 6.06 68 3.25 ± 0.23 
63 >100 69 11.30 ± 1.27 
64 45.76 ± 2.45   
Table 5. Antiproliferative activities against the MCF-7 cell line for acyclic N-1”- and N-3”- 
pyrimidines (59-66) and N-9”- and N-7” purines (67-69). 
Compounds 48 and 57 were selected to identify the molecular key targets of its anti-cancer 
activity (Díaz-Gavilán et al., 2008a). Completion of the human genome sequence and the 
advent of DNA microarrays using cDNAs enhanced the detection and identification of 
hundreds of differentially expressed genes in response to anticancer drugs. In this way 
gene-expression patterns of treated human breast cancer cells in comparison with parental 
MCF-7 cells were obtained. For this purpose, the expression of about 22,000 different human 
genes was analyzed using the Agilent 60-mer oligo microarray platform and the Human 1A 
Oligo Microarray Kit (V2) (Agilent Technologies, CA, USA). 
The up-regulated and the down-regulated genes include genes that encode for different 
metabolic pathways, cellular development process, signal molecules, response to stress, 
regulation of the cell cycle and apoptosis, etc. Analysis of the mRNAs, which are 
deregulated (up-regulated or down-regulated) at least 2-fold in treated cells, revealed the 
following results: 26 genes up-regulated and 59 genes down-regulated in 48-MCF-7 treated 
cells; and 26 genes up-regulated and 17 genes down-regulated in 57-treated human breast 
cancer cells. Each compound revealed a somewhat unique expression pattern together with 
the up-regulation of significant genes involved in different cellular functions and a 
significant down-regulation of genes for 48. One of the more important results in the current 
study was the ability of 48 to modulate the expression of genes involved in apoptosis or its 
delay of mitosis. This effect can be explained by the accumulation of cells in the G2/M 
checkpoint of cell cycle, particularly GP132, the receptor for an unknown ligand, which 
activates a G2 alpha protein (Díaz-Gavilán et al., 2008a). This is transcriptionally up-
regulated by stress-inducing and cell-damaging agents and that is involved in caspase-
mediated apoptosis (Lin & Ye, 2003). Similarly, the ERN1 gene that belongs to the Ser/Thr 
protein kinase family is a potent unfolded-protein response transcriptional activator and 
acts by triggering growth arrest and apoptosis (Yoneda et al., 2001). However, 57 induced 
the down-regulation of a gene involved in the metastatic progression of cancer such as 
RAC1, a Ras-like protein member of the Rho family of the GTPase key downstream target in 
Ras signalling (Baugher et al., 2005). 
The studies by microarray technology showed that the main molecular targets of some of these 
compounds (48 and 57) are pro-apoptotic genes with protein kinase activity such as GP132, 
ERN1 or RAC1, which prevent the metastatic progression (Díaz-Gavilán et al., 2008a). 
5. Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxathiin-3-
ylmethyl)-9H-purines 
The 2,3-dihydro-1,4-benzodioxin ring system is present in a large number of structures of 
therapeutic agents possessing important biological activities (Guillaumet, 1996). Some of them 
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are antagonists of α-adrenergic receptors, giving them antihypertensive properties (Quaglia et 
al., 1999; Pallavicini et al., 2006). Others have affinities with serotonin receptors which are 
involved in nervous breakdown and schizophrenia (Birch et al., 1999). Sixteen years ago, 2,3-
dihydro-1,4-benzodioxins were developed as inhibitors of 5-lipoxygenase, an enzyme 
involved in the oxygenation of arachidonic acid to the leukotriens; they are also useful for the 
treatment of inflammatory diseases such as asthma and arthritis (Satoh et al., 1995). The 
occurrence of the 2,3-dihydro-1,4-benzodioxin structure in various naturally abundant 
compounds has been also reported (Fukuyama et al., 1992). Paradoxically, despite the 
considerable development of biologically active compounds with the 2,3-dihydro-1,4-
benzodioxin moiety, the 2,3-dihydro-1,4-benzoxathiin skeleton has still remained inaccessible. 
The importance of 5-FU as the first-choice drug in carcinomas of the gastrointestinal tract is 
well known despite its side-effects. With the aim of diminishing the toxicity and obtaining 
biologically active derivatives of 5-FU suitable for oral administration great effort has been 
made in the preparation of 5-FU prodrug derivatives. A review of the literature on the 
various prodrugs of 5-FU has been published (Malet-Martino et al., 2002). Various 5-FU 
prodrugs are active against certain malignant cell lines due to an inhibition of thymidilate 
synthase by the formation of 5-fluorodeoxyuridine monophosphate or by the incorporation 
of 5-fluorouridine triphosphate into RNA. During various synthetic studies on masked 5-FU 
derivatives, it has been found that the bond strength between the N-1 atom in the 5-FU ring 
and its N-1 substituent is an important factor influencing the antitumour activity and the 
toxicity of the compounds. The previous results indicated that the weaker the bond strength, 
the stronger are the antitumour activity and the toxicity of the masked compounds (Ozaki, 
1996). In the case of N-alkyl-5-FU derivatives, the strong N-15-FU-Cexocyclic bond conversely 
prevented these derivatives from being easily hydrolyzed in vivo and showed no antitumour 
activity against L1210 leukaemia (Ozaki, 1996). When oxygen was introduced at the α-
position to the alkyl group, the N-C bond became labile under hydrolytic conditions and the 
resulting derivatives showed antitumour activity.  
As it has been demonstrated before, compounds 4-6, 8-10 may be considered as drugs with 
their own entity and antitumour activity independent of that of 5-FU. If the previously 
described compounds are not prodrugs, it is not necessary to maintain the O,N-acetalic 
characteristic with the corresponding weakness of the O,N-acetalic bond. Therefore, 
molecules are being designed in which both structural entities (such as the 
benzoheterocyclic ring and the purine base) are linked by a heteroatom-C-C-base-N-atom 
bond. Very recently the design, synthesis and biological evaluation of a series of 2- and 6-
disubstituted (RS)-9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-purine derivatives 70-80  
were described [Figure 5, Table 6] (Díaz-Gavilán et al., 2008b).  
 
O
S
N
N
N N
R2
R1
  70 R1 = H, R2 = Cl
  71  R1 = H; R2 = Br
  72  R1 = H; R2 = SMe
  73  R1 = H; R2 = OPh
  74  R1 = H; R2 = SPh
  75  R1 = H; R2 = NHPh
  76  R1 = H; R2 = OCH2CH=CH2
  77  R1 = H; R2 = OCH2Ph
  78  R1 = H; R2 = SCH2Ph
  79  R1 = H; R2 = OCH2C6H11
  80  R1 = Cl; R2 = Cl  
Fig. 5. The 1,4-benzoxathiin system linked to several purines. 
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Compound IC50 (μM) Compound IC50 (μM) Compound IC50 (μM) 
5-FU 4.32 ± 0.02 73 20.5 ± 1.11 77 23.2 ± 1.26 
70 10.6 ± 0.66 74 10.5 ± 1.06 78 16.7 ± 3.03 
71 6.18 ± 1.70 75 11.2 ± 2.73 79 17.4 ± 1.60 
72 20.5 ± 1.81 76 17.5 ± 0.25 80 8.97 ± 0.83 
Table 6. Antiproliferative activities against the MCF-7 cell line for 5-FU (Villalobos et al., 
1995), and the six-membered alkylated purine derivatives. 
The three most potent compounds (70, 71 and 80) were subjected to cell cycle and apoptosis 
studies on the MCF-7 human breast cancer cell line (Table 7). The following two 
consequences can be stated: (a) in contrast to 5-FU, the six-membered compounds 70, 71 and 
80, provoked a G0/G1-phase cell cycle arrest when the MCF-7 cells were treated during 48 h 
with the IC50 of the compounds, mainly at the expense of the S-phase populations. The fact 
that at similar doses the novel derivatives exhibit different sequences of cell cycle 
perturbations in comparison with 5-FU indicates that these compounds act by different 
pathways (Marchal et al., 2004). In the case of 71 it is worth pointing out that, moreover, 
there is an increase in the G2/M-phase of the cancerous cells; and (b) the apoptotic indices of 
the target compounds are very important, especially for 80 (58.29% for 70, 63.05% for 71, and 
76.22% for 80). Up to now and according to our knowledge, compound 80 is the most 
important apoptotic inducer against the MCF-7 human breast cancer cell line so far 
reported. 
 
Compound Cell cyclea Apoptosisb 
 G0/G1 S G2/M  
Control 58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
5-FUc 58.07 ± 0.11 39.38 ± 0.98 2.10 ± 0.12 52.81 ± 1.05 
70 69.71 ± 1.50 23.73 ± 1.65 6.56 ± 0.17 58.29 ± 0.75 
71 62.85 ± 0.87 26.71 ± 1.25 10.43 ± 0.38 63.05 ± 0.26 
80 70.30 ± 0.32 23.67 ± 2.40 6.06 ± 2.72 76.22 ± 2.02 
a Determined by flow cytometry (Marchal et al., 2004). 
b Apoptosis was determined using an Annexin V-based assay (Marchal et al., 2004). The data indicate 
the percentage of cells undergoing apoptosis in each sample. 
c Data were taken from ref. (Campos et al., 2005). All experiments were conducted in duplicate and gave 
similar results. The data are means ± SEM of three independent determinations. 
Table 7. Cell cycle distribution and apoptosis induction in the MCF-7 human breast cancer 
cell line after treatment for 48 h for the three most active compounds as antiproliferative 
agents. 
6. Conclusion 
Breast cancer is the commonest malignancy in women and comprises 18% of all cancers in 
women. Normal breast development is controlled by a balance between cell proliferation 
and apoptosis, and there is strong evidence that tumour growth is not just a result of 
uncontrolled proliferation but also of reduced apoptosis. The balance between proliferation 
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and apoptosis is crucial in determining the overall growth or regression of the tumour in 
response to chemotherapy, radiotherapy and more recently, hormonal treatments. All of 
these approaches act in part by inducing apoptosis. Understanding these relationships could 
allow individually tailored treatments to maximize tumour regression and efficacy of 
treatment. It could also help to answer why some tumours fail to respond and thereby 
indicate new routes of drug development.  
Starting from Ftorafur, a known 5-FU prodrug, which shows an 58% apoptosis induction in 
the MCF-7 human breast cancer cell line after treatment for 48 h, the seven-membered 
cyclohomologue 5-FU O,N-acetal 3 and the benzo-fused dihydro oxepine O,N-acetal 8 
present apoptosis inductions higher than 50%. By using molecular modification strategies 
widely used in medicinal chemistry, lately compounds 23 and 28, having in common the 
benzo-fused 2,3-dihidro-5H-1,4-dioxepin and a 6-substituted purine moieties, show 73% and 
65% apoptosis inductions. Finally and following our Drug Anticancer Programme, the 
benzo-fused 1,4-oxathiane moiety linked to the N-9 atom of a 2,6-dichloropurine 80 was 
designed and synthesized. According to our knowledge this is the most important apoptotic 
inducer against the MCF-7 human breast cancer cell line so far reported. This compound is a 
more potent apoptosis inductor than the clinically-used drug paclitaxel (Taxol®), which 
induced programmed cell death up to 43% of cell population. Their mechanisms of action at 
molecular level are being studied at present. 
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